An Open-label, Single Arm, Sequential, Single Centre Trial Investigating the Influence of Oral Semaglutide (NNC0113-0217) on Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects

Registration

Registration

NCT02070510

Study type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Phase

PHASE1

Masking

NONE

Status

COMPLETED

Enrollment

52

Start

2014-02-27

Primary completion

2014-08-20

Lead sponsor

Novo Nordisk A/S

Conditions

Diabetes; Healthy

Interventions

DRUG:semaglutide; DRUG:lisinopril; DRUG:warfarin; DRUG:placebo

Results posted

FALSE

Secondary identifiers

EUDRACT_NUMBER:2013-001087-39; OTHER:U1111-1140-3741

Registered primary outcomes

• Area under the S-warfarin concentration-time curve [From dosing to infinity calculated from a 0-168 hours S-warfarin concentration-time-curve based on 18 sampling time points]
• Area under the R-warfarin concentration-time curve [From dosing to infinity calculated from a 0-168 hours S-warfarin concentration-time-curve based on 18 sampling time points]
• Area under the lisinopril concentration-time curve [From dosing to infinity calculated from a 0-60 hours lisinopril concentration-time-curve based on 13 sampling time points]